Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Design Therapeutics (NASDAQ:DSGN) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Design Therapeutics (NASDAQ:DSGN) was given a new $14.00 price target on by analysts at Leerink Partners.
Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]